Raymond James Financial
SYRE icon

Raymond James Financial’s Spyre Therapeutics SYRE Stock Holding History

Raymond James Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$996K Buy
+19,755
New +$745K ﹤0.01% 3842
2025
Q3 		– Sell
-16
Closed -$240 – 6578
2025
Q2 		$240 Buy
+16
New +$237 ﹤0.01% 6760

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Raymond James Financial's SYRE Position: Q1 2026 in Review

Raymond James Financial opened a new position in Spyre Therapeutics (SYRE) in Q1 2026: 19,755 shares worth $996K. The stake represents ﹤0.01% of the portfolio and ranks #3842 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in SYRE as recently as Q2 2025.

Raymond James Financial first reported a position in SYRE in Q2 2025 and has held it in 2 quarters since. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Raymond James Financial held 19,755 shares of Spyre Therapeutics worth $996K as of Q1 2026.
  • Spyre Therapeutics was a new Raymond James Financial position in Q1 2026.
  • Spyre Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #3842 holding.
  • Raymond James Financial first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.